<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171859</url>
  </required_header>
  <id_info>
    <org_study_id>DOXYTUDCA2010</org_study_id>
    <secondary_id>2010-020422-17</secondary_id>
    <nct_id>NCT01171859</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis</brief_title>
  <official_title>A Single Center, Twelve-month, Open-label, Prospective Study Followed by a Six-month Withdrawal Period to Evaluate the Efficacy, Tolerability, Safety and Pharmacokinetics of Doxycycline in Combination With Tauroursodeoxycholic Acid in Transthyretin Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to explore the potential benefits of a twelve-month doxycycline&#xD;
      (at the best tolerated dose of 200 mg/day) and tauroursodeoxycholic acid (750 mg/day)&#xD;
      treatment on disease progression in patients affected by transthyretin amyloidosis,&#xD;
      including: 1) patients not eligible for liver transplantation; 2) patients eligible for liver&#xD;
      transplantation, as a &quot;bridge&quot; therapy between the time of diagnosis and surgery, with the&#xD;
      aim of stabilizing the disease; 3) patients showing disease progression after liver&#xD;
      transplantation performed since at least 1 year.&#xD;
&#xD;
      It is a phase II, therapeutic exploratory, two-part, 18-month, single centre, prospective&#xD;
      study.&#xD;
&#xD;
      Part I is a 12-month, open label treatment period in which doxycycline (200 mg/day,&#xD;
      continuously) and tauroursodeoxycholic acid (750 mg/day continuously) are administered to 40&#xD;
      consenting subjects with transthyretin amyloidosis. Part II is a withdrawal period in which&#xD;
      subjects will be monitored for disease progression. During part I, subjects will be evaluated&#xD;
      at baseline (study Day 0), and then after 3, 6, 9 and 12 months of doxycycline plus&#xD;
      tauroursodeoxycholic acid treatment or at premature treatment discontinuation; during part&#xD;
      II, they will be assessed at months 15 and 18. Monthly phone contacts and blood tests will be&#xD;
      performed to monitor potential adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to doxycycline + tauroursodeoxycholic acid treatment</measure>
    <time_frame>One year</time_frame>
    <description>A responder is a subject with:&#xD;
a modified body mass index (mBMI) reduction of less than 10% and a change in the Neurologic Impairment Score-Lower Limbs (NIS-LL) &lt;2 (in subjects with peripheral neuropathy);&#xD;
a modified body mass index (mBMI) reduction of less than 10% and an increase in N-terminal natriuretic peptide type B (NT-proBNP) concentration of less than 30% or &lt; 300 pg/mL (in subjects with isolated cardiomyopathy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients experiencing treatment-emergent adverse events</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Every six months</time_frame>
    <description>SF-36 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>doxycycline pharmacokinetics (PK)</measure>
    <time_frame>Every three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response in autonomic dysfunction, sensory-motor peripheral neuropathy and visceral organ involvement</measure>
    <time_frame>One year</time_frame>
    <description>response assessed according to the Kumamoto Scale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurologic response</measure>
    <time_frame>One year</time_frame>
    <description>response assessed by motor and sensory nerves conduction studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients discontinuing from the study because of clinical or laboratory adverse events</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Transthyretin Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Doxycycline + Tauroursodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline + Tauroursodeoxycholic acid</intervention_name>
    <description>doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months</description>
    <arm_group_label>Doxycycline + Tauroursodeoxycholic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy&#xD;
             of green birefringent material in Congo red-stained tissue specimens;&#xD;
&#xD;
          -  Molecular definition of the transthyretin (TTR) mutation or immunohistochemical&#xD;
             staining of amyloid fibrils with anti-TTR antibody;&#xD;
&#xD;
          -  ECOG performance status (PS) 0, 1, 2;&#xD;
&#xD;
          -  New York Heart Association (NYHA) class ≤III&#xD;
&#xD;
          -  Systolic blood pressure ≥100 mmHg (standing)&#xD;
&#xD;
          -  Must have symptomatic organ involvement with amyloid to justify therapy; must have&#xD;
             evidence of neuropathy and/or cardiomyopathy progression after liver transplantation&#xD;
             performed since at least one year.&#xD;
&#xD;
          -  Contraception for women of childbearing potential. Medically approved contraception&#xD;
             could include abstinence. A negative serum pregnancy test is required prior to&#xD;
             initiation of treatment with study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver transplantation in the previous 12 months or liver transplantation anticipated&#xD;
             in less than 6 months;&#xD;
&#xD;
          -  ALT and/or AST ≥ 2 x Upper Normal Limit (UNL);&#xD;
&#xD;
          -  Alkaline phosphatase ≥ 2 x UNL;&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 ml/min;&#xD;
&#xD;
          -  Any other lab values that in the opinion of the investigator might place the subject&#xD;
             at unacceptable risk for participation in the study;&#xD;
&#xD;
          -  Echocardiographic ejection fraction &lt; 50%;&#xD;
&#xD;
          -  Other neuropathies, due to vitamin B12 deficiency, alcoholism, hypothyroidism, uremia,&#xD;
             diabetes mellitus, vasculitides;&#xD;
&#xD;
          -  History of poor compliance;&#xD;
&#xD;
          -  History of hypersensitivity to any of the ingredients of the study therapies;&#xD;
&#xD;
          -  Use of any investigational drug, device (or biologic) within 4 weeks prior to study&#xD;
             entry or during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giampaolo Merlini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amyloid Research and Treatment Centre, Biotechnology Research Laboratories</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006 Feb;20(2):234-9.</citation>
    <PMID>16449795</PMID>
  </reference>
  <reference>
    <citation>Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta. 2008 Sep;1782(9):517-22. doi: 10.1016/j.bbadis.2008.05.005. Epub 2008 Jun 3.</citation>
    <PMID>18572024</PMID>
  </reference>
  <reference>
    <citation>Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010 Jul 30;8:74. doi: 10.1186/1479-5876-8-74.</citation>
    <PMID>20673327</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>July 27, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Giampaolo Merlini</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>amyloidosis</keyword>
  <keyword>transthyretin</keyword>
  <keyword>doxycycline</keyword>
  <keyword>Tauroursodeoxycholic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ursodoxicoltaurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

